Value of Raw Rhubarb Solution in the Precaution of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in Patients with High-Risk Factors: A Predictive Random Compared Research in One Center
- 230 Downloads
Background and aims
Post-ERCP pancreatitis and hyperamylasemia are common complications of endoscopic retrograde cholangiopancreatography (ERCP), especially in high-risk patients. The aim of this study is to evaluate whether a raw rhubarb solution can reduce the incidence of PEP and post-ERCP hyperamylasemia.
From October 2012 to October 2013, 2100 patients received ERCP in our Endoscopic Center. Five hundred patients with high-risk factors were enrolled randomly into the raw rhubarb group (RG, 250 cases drank a raw rhubarb soak solution per 3 h until defecation after ERCP) and the control group (CG, 250 cases drank water after ERCP) in the study. The serum amylase concentration was measured. The abdominal pain, purge time and symptoms of patients were observed in the two groups.
There were no differences in patient demographics, medical history, ERCP procedure, and patient- and procedure-related high-risk factors between the two groups. PEP incidence was 2% (5/250) in the RG group, which was lower than that in the CG group (7.6%, 19/250) (P < 0.01). The rate of post-ERCP hyperamylasemia was 5.2% (13/250) and 16.8% (42/250) in the RG group and CG group, respectively. The incidence of hyperamylasemia in the RG group was significantly lower than that in the CG group (P < 0.01). The incidence of abdominal pain 24 h after ERCP in the RG group was lower than that in the CG group (P < 0.01). No side effects were observed for raw rhubarb solution.
A raw rhubarb solution is safe and effective in preventing the incidence of PEP and hyperamylasemia in high-risk patients.
KeywordsRaw rhubarb Post-ERCP pancreatitis (PEP) Hyperamylasemia Endoscopic retrograde cholangiopancreatography (ERCP)
Endoscopic retrograde cholangiopancreatography
Raw rhubarb group
Sphincter of Oddi dysfunction
Nonsteroidal anti-inflammatory drugs
- WHO ICTRP
The International Clinical Trials Registry Platform from the World Health Organization
White blood cell count
Endoscopic naso-biliary drainage
Endoscopic papillary balloon dilatation
Stromal cell-derived factor-1
Sarcoplasmic reticulum Ca2+-adenosinetriphosphatase
Analysis of variance
The study was supported by the Public Health Office of Jiangxi Province of China (grant no. 20155161) and the First Affiliated Hospital of Nanchang University.
Compliance with ethical standards
Conflicts of interest
The authors have no conflicts of interest to disclose.
- 16.Wang ZK, Yang YS, Cai FC, et al. Is prophylactic somatostatin effective to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis or hyperamylasemia? A randomized, placebo-controlled pilot trial. Chin Med J (Engl). 2013;126:2403–2408.Google Scholar
- 30.Sugano K, Kontani T, Katsuo S, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2012;47:540–552.CrossRefPubMedPubMedCentralGoogle Scholar